Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
From MaRDI portal
(Redirected from Publication:5367394)
Recommendations
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Adaptive designs for dose-finding based on efficacy-toxicity response
Cited in
(30)- Sequential multiple assignment randomized trial (SMART) with adaptive randomization for quality improvement in depression treatment program
- A Bayesian phase I/II clinical trial design in the presence of informative dropouts
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- Modeling heterogeneity in the assessment of treatment effects on tumor development while accounting for monotone dropout
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- A Bayesian Approach to Dose-Response Assessment and Synergy and Its Application to In Vitro Dose-Response Studies
- A utility approach to individualized optimal dose selection using biomarkers
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Adaptive Bayesian compound designs for dose finding studies
- A Bayesian machine learning approach for optimizing dynamic treatment regimes
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Learning optimal personalized treatment rules in consideration of benefit and risk: with an application to treating type 2 diabetes patients with insulin therapies
- An adaptive trial design to optimize dose-schedule regimes with delayed outcomes
- scientific article; zbMATH DE number 2242805 (Why is no real title available?)
- Estimating individualized treatment rules with risk constraint
- DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Optimal Treatment Regimes: A Review and Empirical Comparison
- uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials
- Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups
- Controlling Cumulative Adverse Risk in Learning Optimal Dynamic Treatment Regimens
- A biomarker-based dose-schedule optimization design for immunotherapy trials
- Bayesian multi-arm de-intensification designs
- An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials
- A generalized outcome-adaptive sequential multiple assignment randomized trial design
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- A Bayesian dose-finding design for drug combination trials with delayed toxicities
This page was built for publication: Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5367394)
